Press releases
Year-end report July 1, 2021 – June 30, 2022
30 August, 2023By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the fourth quarter (2022-04-01 – 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]
Interim report July 1, 2022 – March 31, 2023
28 April, 2023By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the third quarter (2023-01-01 – 2023-03-31) Patient recruitment has begun for the Multiple Myeloma study […]
DexTech Medical informerar om myelomstudien
27 March, 2023Bolagets Fas 1-studie avseende effekt av OsteoDex på patienter med multipelt myelom (MM) har initierats och rekrytering av patienter påbörjats. Studien omfattar 20 patienter och genomförs initialt vid tre sjukhus […]
Half-year report July 1 – December 31, 2022
15 February, 2023Summary of the second quarter (2022-10-01 – 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,2 (-1,1) Earnings per share* SEK -0.06 (-0.08) * Before […]
DexTech Medical decision on allocation regarding incentive programs
17 November, 2022At the Annual General Meeting of DexTech AB (“DexTech” or the “Company”) on 28 October 2022, it was resolved to introduce an incentive program (“W 2022 /2025”) for pre-selected key […]
Bulletin from the Annual General Meeting
28 October, 2022Today, 28 October 2022, the Annual General Meeting of DexTech Medical AB was held. All decisions were taken by the required majority. Resolution on adoption of the income statement and […]
Interim report July 1 – September 30, 2022
27 October, 2022Summary of the first quarter (2022-07-01 – 2022-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -0,8 (-0,9) Earnings per share* SEK -0,04 (-0.06) Cash and […]
Dextech Medical AB (publ) Notice to AGM 2022
28 September, 2022WELCOME TO THE ANNUAL GENERAL MEETING 2022 IN DEXTECH MEDICAL AB (publ) Dextech Medical AB’s shareholders are welcome to attend the Annual General Meeting that is taking place on Friday, […]
DexTech Medical announces upcoming multiple myeloma study
27 September, 2022The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the Medical Products Agency on August 10, […]
Dextech Medical AB Annual report 210701-220630
20 September, 2022Download the annual report below. Dextech Medical AB Annual report 210701-220630